CYP2D6 and breast carcinoma: Thus, this study aimed to investigate, in a large real-world population with long follow-up, the impact of the tamoxifen dose coverage, CYP2D6*4 haplotype, and concomitant use of SSRIs, in addition to other non-genetic factors, on tamoxifen-treated breast cancer survival.